Mindwalk Holdings Corp. · NASDAQ:HYFT
Mindwalk — ImmunoPrecise Antibodies — Q3 FY2025 Earnings Presentation
16 slides from Mindwalk's earnings presentation, Mar 28, 2025
Slide 1: FY 2025 Q3 Earnings Presentation
FY 2025 Q3 Earnings Presentation March 28, 2025 | ir.ipatherapeutics.com | NASDAQ: IPA Presented by Dr. Jennifer Bath, IPA CEO
Slide 2: Disclosures
Disclosures Disclaimer This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of Immuno Precise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the faciliti
Slide 3: Fiscal Year 2025 Q3 Business Update
Fiscal Year 2025 Q3 Earnings Call Fiscal Year 2025 Q3 Business Update ir.ipatherapeutics.com | NASDAQ:IPA ©2025 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a tra demark of ImmunoPrecise Antibodies LTD. BioStrand is a n independently operating s ubsidiary of IPA. BioStrand and LENSai ar
Slide 4: Capital raise and financial strategy
Fiscal Year 2025 Q3 Earnings Call Corporate Update Capital raise and financial strategy Capital raise Cash balance at close of Q3 2025 $8.8 Million (USD) $12.9 million (CAD) • Raised through our Extending runway significantly and At-The-Market (ATM) facility offsetting short-term financing risk • Us
Slide 5: Maintained position during sector downturn
Fiscal Year 2025 Q3 Earnings Call Corporate Update Commitment to financial discipline Maintained position during sector downturn Proactive strategy • Streamline structure • Introduce new leadership • Preparation to roll out a series of strategic initiatives ir.ipatherapeutics.com | NASDAQ:IPA ©2025
Slide 6: Leadership expansion and Boston team expansion
Fiscal Year 2025 Q3 Earnings Call Corporate Update Leadership expansion Boston team expansion Dr. Kamil Isaev Joe Scheffler Dr. Li Hui Interim Chief Financial Officer Sr. Director, Client Relations joins board – Over 15 years experience Experience in AI, in antibody development. semiconductor techno
Slide 7: Strategic partnership with global bioscience leader
Fiscal Year 2025 Q3 Earnings Call Corporate Update Strategic partnership with global bioscience leader Pipeline update $8-10M (USD) Next-Gen GLP-1 manufacturing Cancer Therapeutic initiated to support Partnership preclinical development •Multi-billion-dollar bioscience company •AI-designed program •
Slide 8: Technology advancements: De novo antibody design
Fiscal Year 2025 Q3 Earnings Call Corporate Update Technology advancements De novo Vultr partnership: AWS Marketplace antibody design: • Building out scalable cloud integration and • Large pharma partner infastructure expansion: initiated a de novo • Detailed case study, now • December 2024 - submit
Slide 9: Divestiture initiative update and Strategic Development
Fiscal Year 2025 Q3 Earnings Call Corporate Update Divestiture initiative update Strategic Development Process has progressed Unified rebrand underway • Bringing all IPA entities under a Two European wet labs single brand. • Utrecht • Enhancing global visibility • Oss, the Netherlands • Building str
Slide 10: Fiscal Year 2025 Q3 Financial Update
Fiscal Year 2025 Q3 Earnings Call Fiscal Year 2025 Q3 Financial Update ir.ipatherapeutics.com | NASDAQ:IPA ©2025 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a tra demark of ImmunoPrecise Antibodies LTD. BioStrand is a n independently operating s ubsidiary of IPA. BioStrand and LENSai a
Slide 11: Quarterly Revenue
Fiscal Year 2025 Q3 Earnings Call Quarterly Revenue Al l values listed i n CAD. ir.ipatherapeutics.com | NASDAQ:IPA ©2025 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a tra demark of ImmunoPrecise Antibodies LTD. BioStrand is a n independently operating s ubsidiary of IPA. BioStrand and
Slide 12: BioStrand Revenue Growth (FY22-FY25 YTD)
Fiscal Year 2025 Q3 Earnings Call BioStrand Revenue Growth (FY22-FY25 YTD) Al l values listed i n CAD. ir.ipatherapeutics.com | NASDAQ:IPA ©2025 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a tra demark of ImmunoPrecise Antibodies LTD. BioStrand is a n independently operating s ubsidiar
Slide 13: Focus on growth through R&D and Sales & Marketing
Fiscal Year 2025 Q3 Earnings Call Focus on growth through R&D and Sales & Marketing Al l values listed i n CAD. ir.ipatherapeutics.com | NASDAQ:IPA ©2025 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a tra demark of ImmunoPrecise Antibodies LTD. 13
Slide 14: Net loss of $21.5M
Fiscal Year 2025 Q3 Earnings Call Net loss of $21.5M, equivalent to ($0.66) per share (basic & diluted) Net loss pre-impairment, net of tax $2.9M, equivalent to ($0.09) per share (basic & diluted) Net Loss Earnings Per Share Q3 FY25 No Impairment Q3 FY24 Q3 FY25 No Impairment Q3 FY24 $0,0 M $0,00 -$
Slide 15: Ending Quarterly Cash Balance of $13M
Fiscal Year 2025 Q3 Earnings Call Ending Quarterly Cash Balance of $13M Nine Months Ended Jan 31, 2025 $15,3 M $9,6 M -$0,4 M -$5,3 M Ops Burn Capex & LHI Financing Total Cash Provided Al l values listed i n CAD. ir.ipatherapeutics.com | NASDAQ:IPA ©2025 ImmunoPrecise Antibodies LTD. All rights rese
Slide 16: Q&A FY 2025 Q3 Earnings Call
Q&A FY 2025 Q3 Earnings Call The HUB of March 28, 2024| ir.ipatherapeutics.com | NASDAQ: IPA TSXV: IPA Biotherapeutic ©2025 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a tra demark of ImmunoPrecise Antibodies LTD. BioStrand is a n independently operating s ubsidiary of ImmunoPrecise An
ImmunoPrecise Antibodies — Q3 FY2025 Earnings Presentation on 6ix